<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01365663</url>
  </required_header>
  <id_info>
    <org_study_id>SPC4955-901</org_study_id>
    <secondary_id>EudraCT 2010-024363-40</secondary_id>
    <nct_id>NCT01365663</nct_id>
  </id_info>
  <brief_title>Multiple Ascending Dose Study of SPC4955 in Healthy Subjects</brief_title>
  <official_title>A First-in-Human (FIH), Randomized, Dose-Escalation, Double-Blind, Placebo-Controlled Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SPC4955 Administered to Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Santaris Pharma A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Santaris Pharma A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to study safety and tolerability of SPC4955 in healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects experiencing adverse events</measure>
    <time_frame>up to 78 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak Plasma Concentration (Cmax) of SPC4955</measure>
    <time_frame>Up to 78 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>total Cholesterol</measure>
    <time_frame>up to 78 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) of SPC4955</measure>
    <time_frame>Up to 78 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDL</measure>
    <time_frame>up to 78 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HDL</measure>
    <time_frame>up to 78 days</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.25 mg/kg in Healthy Subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5 mg/kg in Healthy Subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.0 mg/kg in Healthy Subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.5 mg/kg in Healthy Subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2.0 mg/kg in Healthy Subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline 0.9%</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPC4955</intervention_name>
    <description>3 Weekly SC injections</description>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPC4955</intervention_name>
    <description>3 Weekly SC injections</description>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPC4955</intervention_name>
    <description>3 Weekly SC injections</description>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPC4955</intervention_name>
    <description>3 Weekly SC injections</description>
    <arm_group_label>Cohort 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPC4955</intervention_name>
    <description>3 Weekly SC injections</description>
    <arm_group_label>Cohort 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline 0.9%</intervention_name>
    <description>3 Weekly SC injections</description>
    <arm_group_label>Saline 0.9%</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male or female subjects, age 18-65 years, inclusive.

          2. BMI 18-33 kg/m2

          3. Screening hematology, clinical chemistries, coagulation and urinalysis consistent with
             overall good health and the following criteria are met:

               -  LDL-C ≥3.24 mmol/L (≥125 mg/dL)

               -  Triglycerides (fasted) &lt;2.7mmol/L (&lt;239 mg/dL)

               -  ALT within normal limits

        Exclusion Criteria:

          1. Any uncontrolled or active major systemic disease including, but not limited to:
             cardiovascular, pulmonary, gastrointestinal, metabolic, urogenital, neurological,
             immunological, psychiatric, or neoplastic disorder with metastatic potential.

          2. History or presence of malignancy within the past year. Subjects who have been
             successfully treated (for 3 months or longer) with no recurrence of basal cell
             carcinoma of the skin or carcinoma in-situ of the cervix may be enrolled

          3. Active acute or chronic infection, including, but not limited to: upper airway
             infection, urinary tract infection, and skin infection

          4. Use of prescription medication within 14 days prior to the planned first drug
             administration and throughout the study.

          5. Use of non-prescription or over-the-counter medications is prohibited within 7 days
             prior to the planned first drug administration and throughout the study. This includes
             all vitamins, herbal supplements, or remedies.

          6. Positive results on the following Screening laboratory tests: urine pregnancy test
             (women only), alcohol breath test, urine drugs of abuse, hepatitis B surface antigen,
             hepatitis C antibody, and human immunodeficiency virus (HIV) antibody.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Werner Feuerer, Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nuvisan GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nuvisan GmbH</name>
      <address>
        <city>Neu-Ulm</city>
        <zip>89231</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 18, 2011</study_first_submitted>
  <study_first_submitted_qc>June 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2011</study_first_posted>
  <last_update_submitted>January 26, 2012</last_update_submitted>
  <last_update_submitted_qc>January 26, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 31, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypercholesterolemia</keyword>
  <keyword>LDL</keyword>
  <keyword>HDL</keyword>
  <keyword>apoB</keyword>
  <keyword>hyperlipidemia</keyword>
  <keyword>LNA-oligonucleotide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

